HighTower Advisors LLC Purchases 3,571 Shares of RxSight, Inc. (NASDAQ:RXST)

HighTower Advisors LLC increased its position in shares of RxSight, Inc. (NASDAQ:RXST) by 37.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,013 shares of the company’s stock after purchasing an additional 3,571 shares during the quarter. HighTower Advisors LLC’s holdings in RxSight were worth $640,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in RXST. Driehaus Capital Management LLC increased its holdings in shares of RxSight by 74.9% during the second quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock worth $42,490,000 after buying an additional 302,367 shares in the last quarter. Brown Capital Management LLC bought a new stake in RxSight during the 3rd quarter worth approximately $26,813,000. Baillie Gifford & Co. grew its position in RxSight by 17.0% during the 3rd quarter. Baillie Gifford & Co. now owns 419,004 shares of the company’s stock worth $20,711,000 after acquiring an additional 60,789 shares during the last quarter. Marshall Wace LLP acquired a new stake in RxSight during the 2nd quarter valued at $19,512,000. Finally, Charles Schwab Investment Management Inc. raised its position in RxSight by 28.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 285,329 shares of the company’s stock valued at $14,104,000 after purchasing an additional 62,507 shares during the last quarter. 78.78% of the stock is owned by institutional investors.

Insider Transactions at RxSight

In other news, Director Jesse Anderson Corley acquired 11,111 shares of RxSight stock in a transaction that occurred on Tuesday, November 12th. The shares were acquired at an average price of $45.37 per share, with a total value of $504,106.07. Following the purchase, the director now directly owns 468,571 shares of the company’s stock, valued at $21,259,066.27. The trade was a 2.43 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ilya Goldshleger sold 3,105 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $46.08, for a total transaction of $143,078.40. Following the completion of the sale, the insider now directly owns 42,246 shares of the company’s stock, valued at $1,946,695.68. The trade was a 6.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,707 shares of company stock worth $3,037,386 in the last three months. Insiders own 9.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on RXST shares. Needham & Company LLC reiterated a “buy” rating and set a $66.00 price target on shares of RxSight in a research report on Friday, September 13th. Jefferies Financial Group assumed coverage on shares of RxSight in a research report on Tuesday, October 29th. They set a “buy” rating and a $72.00 target price on the stock. UBS Group initiated coverage on shares of RxSight in a report on Friday, December 6th. They issued a “buy” rating and a $52.00 price target for the company. Finally, Wells Fargo & Company restated an “equal weight” rating and issued a $42.00 price objective (down previously from $56.00) on shares of RxSight in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $62.13.

RxSight Stock Performance

Shares of RXST stock opened at $38.19 on Friday. The firm’s 50 day moving average price is $46.08 and its two-hundred day moving average price is $50.25. RxSight, Inc. has a 52-week low of $34.92 and a 52-week high of $66.54. The stock has a market cap of $1.54 billion, a PE ratio of -46.01 and a beta of 1.11.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.